Systemic lupus erythematosus is a multi-systemic autoimmune disease distinguished by the presence of various autoantibodies. Like most autoimmune diseases, systemic lupus erythematosus is believed to be induced by a combination of genetic, immunologic, and environmental factors, mainly infectious agents. Molecular mimicry between an infectious antigen and self-components is implicated as a pivotal mechanism by which autoimmune diseases such as systemic lupus erythematosus are triggered. Here we review the current evidence of molecular mimicry between different infectious agents and systemic lupus erythematosus.
Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med2003; 349: 1526-1533.
2.
Shoenfeld Y. , Zandman-Goddard G., Stojanovich L., et al. The mosaic of autoimmunity: hormonal and environmental factors involved in autoimmune diseases-2008. Israel Med Assoc J2008; 10: 8-12.
3.
Damian RTMolecular mimicry: antigen sharing by parasite and host and its consequences . Am Nat1964; 98: 129-149.
4.
Lim DG, Haffler DAMolecular mimicry in multiple sclerosis: role of MHC altered peptide Ligands . In: Infections and Autoimmunity, 1st edn. Amsterdam: Elsevier; 2004. p. 45-55.
5.
Oldstone MBMolecular mimicry and immune-mediated diseases. FASEB J1998; 12: 1255-1265.
6.
Rose NR, Mackay IRMolecular mimicry: a critical look at exemplary instances in human diseases . Cell Mol Life Sci2000; 57: 542-551.
7.
Blank M., Barzilai O., Shoenfeld Y.Molecular mimicry and immunity. Clin Rev Allergy Immunol2007; 32: 111-118.
8.
Srinivasappa J., Saegusa J., Prabhakar BS, et al. Molecular mimicry: frequency of reactivity of monoclonal antiviral Abs with normal tissues. J Virol1986; 57: 397-401.
9.
Yuki N., Susuki K., Koga M., et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci USA2004; 101: 11404-11409.
10.
Guilherme L. , Kalil J., Cunningham MWMolecular mimicry in the autoimmune pathogenesis of rheumatic heart disease. Autoimmunity2006 ; 39: 31-39.
11.
Kirvan CA, Swedo SE, Heuser JS, Cunningham MWMimicry and autoantibody-mediated neuronal cell signaling in Sydenham chorea . Nat Med2003; 9: 914-920.
12.
Cunningham MWStreptococcus-induced myocarditis in mice . Autoimmunity2001; 34: 193-197.
13.
Li Y., Heuser JS, Cunningham LC, et al. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis . J Immunol2006; 177: 8234-8240.
14.
Barzilai O. , Sherer Y., Ram M., et al. Epstein-Barr virus and cytomegalovirus in autoimmune diseases: are they truly notorious? A preliminary report. Ann NY Acad Sci2007; 1108: 567-577.
15.
Niller HH, Wolf H., Minarovits J.Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases. Autoimmunity2008; 41: 298-328.
16.
Toussirot E. , Roudier J.Epstein-Barr virus in autoimmune diseases . Best Pract Res Clin Rheumatol2008; 22: 883-896.
17.
Berkun Y., Zandman-Goddard G., Barzilai O., et al. Infectious antibodies in systemic lupus erythematosus patients . Lupus2009; this issue.
18.
James JA, Neas BR, Moser KL, et al. Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum2001; 44: 1122-1126.
19.
Zandman-Goddard G., Berkun Y., Barzilai O., et al. Exposure to Epstein-Barr virus infection is associated with mild systemic lupus erythematosus disease. Ann NY Acad Sci2009; in press.
20.
Lu JJ, Chen DY, Hsieh CW, et al. Association of Epstein-Barr virus infection with systemic lupus erythematosus in Taiwan. Lupus2007; 16: 168-175.
21.
Poole BD, Templeton AK, Guthridge JM, Brown EJ, Harley JB, James JAAberrant Epstein-Barr viral infection in systemic lupus erythematosus. Autoimmun Rev2009; 8: 337-342.
22.
Sabbatini A., Bombardieri S., Migliorini P.Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA I. Eur J Immunol1993; 23: 1146-1152.
23.
McClain MT, Ramsland PA, Kaufman KM, James JAAnti-Sm autoantibodies in systemic lupus target highly basic surface structures of complexed spliceosomal autoantigens. J Immunol2002; 168: 2054-2062.
24.
James JA, Scofield RH, Harley JBLupus humoral autoimmunity after short peptide immunization. Ann NY Acad Sci1997; 815: 124-127.
25.
McClain MT, Heinlen LD, Dennis GJ, Roebuck J., Harley JB, James JAEarly events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med2005; 11: 85-89.
26.
Sundar K., Jacques S., Gottlieb P., et al. Expression of the Epstein- Barr virus nuclear antigen-1 (EBNA-1) in the mouse can elicit the production of anti-dsDNA and anti-Sm Abs. J Autoimmun2004; 23: 127-140.
27.
Poole BD, Gross T., Maier S., Harley JB, James JALupus-like autoantibody development in rabbits and mice after immunization with EBNA-1 fragments. J Autoimmun2008; 31: 362-371.
28.
Gross AJ, Hochberg D., Rand WM, Thorley-Lawson DAEBV and systemic lupus erythematosus: a new perspective. J Immunol2005; 174: 6599-6607.
29.
Kang I., Quan T., Nolasco H., et al. Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol2004 ; 172: 1287-1294.
30.
McClain MT, Poole BD, Bruner BF, Kaufman KM, Harley JB, James JAAn altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum2006; 54: 360-368.
31.
Berner BR, Tary-Lehmann M., Yonkers NL, Askari AD, Lehmann PV, Anthony DDPhenotypic and functional analysis of EBVspecific memory CD8 cells in SLE . Cell Immunol2005; 235: 29-38.
32.
Schaadt E., Baier B., Mautner J., Bornkamm GW, Adler B.Epstein- Barr virus latent membrane protein 2A mimics B-cell receptor-dependent virus reactivation. J Gen Virol2005; 86: 551-559.
33.
Poole BD, Rechsteiner MP, Berger C., et al. Latent membrane protein 2B regulates susceptibility to induction of lytic Epstein-Barr virus infection. J Virol2008; 82: 1739-1747.
34.
Stathopoulou EA, Routsias JG, Stea EA, Moutsopoulos HM, Tzioufas AGCross-reaction between Abs to the major epitope of Ro60 kD autoantigen and a homologous peptide of Coxsackie virus 2B protein . Clin Exp Immunol2005; 141: 148-154.
35.
Lunardi C., Tinazzi E., Bason C., Dolcino M., Corrocher R., Puccetti A.Human parvovirus B19 infection and autoimmunity. Autoimmun Rev2008; 8: 116-120.
36.
Hirose S., Kaneko Y., Maruyama N., et al. Molecular mimicry between human endogenous retrovirus clone 4-1 and HLA class I antigen with reference to the pathogenesis of systemic lupus erythematosus. Rheumatology1999; 38: 1163-1164.
Gergely P. Jr , Pullmann R., Stancato C., et al. Increased prevalence of transfusion-transmitted virus and cross-reactivity with immunodominant epitopes of the HRES-1/p28 endogenous retroviral autoantigen in patients with systemic lupus erythematosus . Clin Immunol2005; 116: 124-134.
39.
Perl A., Nagy G., Koncz A., et al. Molecular mimicry and immunomodulation by the HRES-1 endogenous retrovirus in SLE. Autoimmunity2008; 41: 287-297.
40.
Brand A., Griffiths DJ, Herve C., Mallon E., Venables PJHuman retrovirus-5 in rheumatic disease. J Autoimmun1999; 13: 149-154.
41.
Blank M., Shoenfeld Y., Perl A.Cross-talk of the environment with the host genome and the immune system through endogenous retroviruses in systemic lupus erythematosus. Lupus2009; this issue.
42.
Shoenfeld Y. , Vilner Y., Coates AR, et al. Monoclonal anti-tuberculosis Abs react with DNA, and monoclonal anti-DNA autoantibodies react with Mycobacterium tuberculosis. Clin Exp Immunol1986; 66: 255-261.
43.
George J., Shoenfeld Y.Infections, idiotypes and SLE. Lupus1995; 4: 333-335.
44.
Unni KK, Holley KE, McDuffie FC, Titus JLComparative study of NZB mice under germ-free and conventional conditions . J Rheumatol1975; 2: 36-44.
45.
Zandman-Goddard G., Shoenfeld YSLE and infections. In: Infections and Autoimmunity, 1st edn. Amsterdam : Elsevier; 2004. p. 491-503.
46.
Zhang W., Reichlin M.A possible link between infection with burkholderia bacteria and systemic lupus erythematosus based on epitope mimicry. Clin Dev Immunol2008; 1-7.
47.
Cervera R., Piette JC, Font J., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum2002; 46: 1019-1027.
Cervera R., Asherson RA, Acevedo ML, et al. Antiphospholipid syndrome associated with infections: clinical and microbiological characteristics of 100 patients. Ann Rheum Dis2004; 63: 1312-1317.
50.
Blank M., Shoenfeld Y., Cabilli S., Heldman Y., Fridkin M., Katchalski-Katzir E.Prevention of experimental antiphospholipid syndrome and endothelial cell activation by synthetic peptides. Proc Natl Acad Sci USA1999; 96: 5164-5168.
51.
Blank M., Kraus I., Fridkin M., et al. Bacterial induction of autoantibodies to beta-2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest2002; 109: 797-804.
52.
Blank M., Asherson RA, Cervera R., Shoenfeld Y.Antiphospholipid syndrome infectious origin. J Clin Immunol2004; 24: 12-23.
53.
Inic-Kanada A., Stojanovic M., Zivkovic I., et al. Murine monoclonal antibody 26 raised against tetanus toxoid cross-reacts with beta2-glycoprotein I: its characteristics and role in molecular mimicry. Am J Reprod Immunol2009; 61: 39-51.
54.
Gharavi EE, Chaimovich H., Cucurull E., et al. induction of anti-phospholipids Abs by immunization with synthetic viral and bacterial peptides. Lupus1999; 8: 449-455.
55.
Gharavi AE, Vega-Ostertag M., Espinola RG, et al. Intrauterine fetal death in mice caused by cytomegalovirus-derived peptide induced aPL antibodies. Lupus2004 ; 13: 17-23.
